|
|
Pulmonary Arterial Hypertension - Group 1: What the Primary Care NP Needs to Know
|
|
Facebook
LinkedIn
E-Mail
|
(826)
Other: Acute Care, Acute Coronary/Cardiac Conditions, Assessment, Best Practices, Cardiovascular, Diagnosis, Diagnostics, EHR (Electronic Health Records), EKG, Evaluation (Follow-up), Evidence-Based Guidelines, Health Promotion, Heart/Chest Sounds, Hypertension, Imaging Selection/Interpretation, Laboratory Interpretation, Pharmacology, Planning, Pregnant Patient , Primary Care, Pulmonary, Radiology, Screening, Treatment, Treatment Plan
(show less)
|
Released: 06/03/2021
Expires: 06/30/2022 (subject to change) - CE for this activity will not be available after this date.
Delivery Note: The content for this activity is available in multiple delivery formats (Live Webinar and Interactive On-Demand) in the AANP CE Center. Learners completing this activity should only complete ONE delivery-method to earn credit. If you already attended and completed Webinar #1 (4/22/21) or Webinar #2 (5/7/21) of this activity, you should not register for or complete the interactive on-demand offering of the same content. Completing multiple delivery options for the same activity is duplicate credit for the same content and may not be accepted by some regulatory bodies.
|
OverviewPulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH), which generally refers to high blood pressure of the arteries of the lungs and may be caused by a variety of conditions. While considered an uncommon condition, if PAH is not treated early, it is associated with worsening symptoms, significant morbidity, and a 5-year survival rate of approximately 40% to 60%. Major challenges in the care of patients with PAH include delayed diagnosis, delayed initiation of appropriate treatment, delayed referral to PAH specialty centers, and underutilization of evidence-based treatment recommendations. Listen to two expert PAH nurse practitioners explain why NPs in primary care have such a crucial role in the management of patients with this complex disease.
Objectives- Describe the disease pathology associated with Group 1 PAH.
- Identify symptoms associated with PAH.
- List evidence-based measures used to establish a diagnosis of PAH.
- Identify when patients with PAH should be referred to PH care centers.
- Describe current evidence-based strategies used to manage PAH.
Speakers
Martha Kingman, FNP, DNP
Susanne E. McDevitt, MSN, ACNP-BC
Disclosure
This program was planned in accordance with AANP CE Standards and Policies.
Speaker Disclosures:
- Martha Kingman, FNP-C, DNP, discloses relationships with the following companies:
- Actelion Pharmaceuticals, US, Inc., Janssen Pharmaceutical Company of Johnson & Johnson: honoraria and speakers bureau for pulmonary hypertension
- Bayer: speakers’ bureau for pulmonary hypertension
- United Therapeutics: speakers’ bureau for pulmonary hypertension
- Susanne E. McDevitt, MSN, ACNP-BC, has received consulting fees for pulmonary hypertension from the following companies:
- Acceleron Pharma
- Bayer
- Janssen
- United Therapeutics
This continuing education activity is supported by an educational grant from Actelion Pharmaceuticals, US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. All other Planners have no relevant financial relationships to disclose.
Disclaimer
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the Pretest associated to the activity.
- Complete the educational content:
- Interactive Presentations: Click the Play button to watch the launch the interactive activity presentation. Full participation credit for the activity will be received once the the end of the interactive content has been reached.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Complete the post-test and pass with a score of at least 70% (4 attempts allowed).
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information
For questions or more information concerning this online CE opportunity contact the AANP CE Center Manager at CECenter@aanp.org.
1.25 Contact Hour(s) of CE,
0.5 of which may be applied towards Pharmacology
|
|
|
|
Adding Registration, Please wait...
